Executive Summary
Spectral MD secured an $86.6M BARDA contract for burn wound imaging R&D, with $49.6M already outlayed on a 7-year deal potentially reaching $127.8M including options, signaling robust federal support for U.S. medtech innovation. This full-competition award to a small business underscores BARDA's commitment to preparedness tech amid high execution already. Investors gain a bullish entry into niche biotech R&D with monitored long-term risks.
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from March 13, 2026.
Investment Signals(1)
- $86.6M BARDA R&D Award(HIGH)▲
$86,574,404 obligated with $49,600,146 outlayed for burn imaging device; options add $41.2M upside to $127.8M total.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
7-year term to 2030-09-30 vulnerable to funding cuts or R&D delays in NAICS 541714 biotech development.
Opportunities(1)
- ◆
$41.2M unexercised options expandable via cost-plus fixed-fee structure.
Sector Themes(1)
- ◆
Full-competition award for PSC 6525 imaging tech highlights federal priority on burn care innovation.
Watch List(1)
- 👁
{"entity"=>"Spectral MD, Inc.", "reason"=>"$49.6M outlays signal revenue ramp; $127.8M ceiling offers 47% growth potential.", "trigger"=>"Option exercises or Q1 2027 outlays >$60M"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC